Sunitinib Benefit Explored in Poor-Prognosis Kidney Cancer

..., July 16 (HealthDay News) -- The oral cancer drug sunitinib (Sutent) has shown promising results in advanced k...arch says. Previous clinical trials showed that sunitinib was effective in patients with advanced kidney can.... All of the patients received 50 milligrams of sunitinib once daily, repeated in six-week cycles (four week...

2-drug combination appears safe and active in metastatic kidney cancer

...apies. "Patients with non-clear cell renal cell cancer, including papillary renal cancer, don't respond as well to tyrosine kinase inhibitors, such as sunitinib and sorafenib, as patients with clear cell renal cell. So there is an unmet need for therapy for these patients. We've seen that this combination may ...

Two Drugs Safe for Rare Forms of Kidney Cancer

...er. "Patients with non-clear cell renal cell cancer, including papillary renal cancer, don't respond as well to tyrosine kinase inhibitors, such as sunitinib [Sutent] and sorafenib [Nexavar], as patients with clear cell renal cell. So there is an unmet need for therapy for these patients. We've seen that th...

NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus

...us (Afinitor(R), Novartis) for advanced renal cell carcinoma in patients whose disease has progressed after treatment with kinase inhibitors such as sunitinib (Sutent(R), Pfizer Inc.) and sorafenib (Nexavar(R), Bayer HealthCare). The FDA approval is based on recent results of a clinical trial whic...

EAU launches new clinical guidelines for 2009 -- kidney cancer

...eatment options. The panel do not recommend Interferon-alpha (IFN-alpha) in a first-line setting as monotherapy in the treatment of metastatic RCC. sunitinib and Bevacizumab + IFN-alpha are recommended as first-line therapy in low- and intermediate-risk patients while Temsirolimus is recommended for hig...

NCCN Presents Updates to NCCN Guidelines for Thyroid Carcinoma

..., small molecule kinase inhibitors such as sorafenib (Nexavar(R), Bayer) or sunitinib (Sutent(R), Pfizer, Inc.) in the treatment of metastatic papillary carcinom...ials have shown that small molecule kinase inhibitors such as sorafenib and sunitinib can be effective," said Dr. Sherman. Also new to the NCCN Guidelines i...

Study sheds light on angiogenesis inhibitors, points to limitations, solutions

... resistance to angiogenesis inhibitor therapy in the journal Nature Reviews Cancer . The scientists tested the effects of the anti-angiogenic drug sunitinib (manufactured as Sutent) in mouse models of both pancreatic neuroendocrine cancer and glioblastoma, the most common type of primary brain tumor. In bo...

UK kidney cancer patients face toxic, out-dated treatments with little hope of change

... considered for these drugs in the UK" says Professor Eisen. "Given that sunitinib was investigated as a first line option, it seemed most likely that it woul... UK clinicians and patients could be well and truly dashed. For example sunitinib has already been adopted in advanced Western countries as the first-line th...

Drug fends off kidney cancer progression

... tumors. More than 400 patients participated in this study, all of whom had disease that had progressed with currently available targeted therapies sunitinib and/or sorafenib. Patients were randomized to receive everolimus or placebo. After six months, 26 percent of patients in the everolimus group had di...

New Drug Duo Helps Cut Colon Cancer Risk

...l side effects, cardiovascular side effects or temporary hearing loss, a rare side effect of DMFO. In the second study, the researchers showed that sunitinib (Sutent) appears effective in slowing tumor growth and cutting the risk of metastases in patients with hepatocellular liver cancer, researchers report...

Sunitinib in Medical Technology

Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

HOUSTON, May 19 /PRNewswire/ -- Agennix announced today that talactoferrin alfa (talactoferrin) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent(R) - Pfizer). ...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - ...

Side Effects of Sunitinib in Kidney Cancer Are 2 to 3 Times More Expensive to Manage Than Those of Avastin Plus Interferon

- Tolerability is an Increasingly Important Factor When Selecting Treatment Options for Patients - ABSTRACT No: 5110 (Poster 6H) BASEL, Switzerland, May 30 /PRNewswire/ -- Data presented at the largest oncology meeting in the world, the American Societ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...nd Drug Administration (FDA) as the first oral, daily therapy (5 mg and 10 mg tablets) to treat advanced kidney cancer after failure of treatment with sunitinib or sorafenib. Recently, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion supporting EU approval of Afinitor to trea...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

... other parts of the body. Even with the recent approval of several biological therapies for the treatment of advanced metastatic RCC (VEGF inhibitors, sunitinib and sorafenib, and mTOR inhibitors everolimus and temsirolimus), the National Cancer Institute reports a rising incidence of RCC with incidence and mo...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... the US as the first oral, daily therapy (5 mg and 10 mg tablets) to treat patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib. Afinitor is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives or to any of the excipients....

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

...pies. Previously conducted preclinical studies combining talactoferrin with sunitinib are supportive for examining this combination in a randomized trial in pati...argeted therapies include multi-targeted tyrosine kinase inhibitors such as sunitinib (Sutent) and sorafenib (Nexavar), inhibitors of the mammalian target of rap...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

...., Texas Oncology-Amarillo: Phase II study of sunitinib malate for metastatic castration-resistant prostat...III randomized study of overall survival with sunitinib versus interferon (IFN)-alfa as first-line tr...noma (mRCC); Multicenter, Phase I/II study of sunitinib in combination with docetaxel and prednisone ...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

...in, J. J. Stephenson, L. Campos, S. P. Chawla, D. R. Spigel, A. Spira Abstract 14565: Phase 1 report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma. Investigators: P. Allerton, B. Ebrahimi, M. T. Schreeder, P. Kaiser, S. P. C...

New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

...it juice may increase plasma concentrations of the major metabolite of TORISEL, and therefore both should be avoided. The combination of TORISEL and sunitinib resulted in dose-limiting toxicity (Grade 3/4 erythematous maculopapular rash, and gout/cellulitis requiring hospitalization). Please see TORISEL fu...

Sunitinib in Medical Dictionary

Kidney cancer

...ing ... The incidence of kidney cancer seems to be increasing, ... Kidney Cancer (Mayo Foundation for Medical Education and Research) ... sunitinib Benefit Explored in Poor-Prognosis Kidney Cancer (07/16/2009, HealthDay) ... Several types of cancer can afflict the kidneys. Renal cell c...

Kidney

...rinary Tract Function, Disorders, and Diseases(American Association ... Links format topics provided by the U.S. National Library of Medicine. ... sunitinib Benefit Explored in Poor-Prognosis Kidney Cancer(07/16/2009, HealthDay) ... Who can be a kidney donor? ... What risks are associated with kid...

Sunitinib in Biological News

Biomarkers allow doctors to match therapy to patient

...s) are a potential biomarker during treatment with sunitinib or bevacizumab: Abstract 4956 Researchers have...octors monitor the effectiveness of treatment with sunitinib or bevacizumab for kidney and non-small cell lung ...or (VEGF) receptor targeted agents bevacizumab and sunitinib have proven effective against several cancers, suc...

Basic research leads to a novel cancer therapy

...m, the tumour shrunk to at least half its size. sunitinib has not yet been approved in Germany, but approval and market entry are expected in this year. sunitinib is administered after diagnosis. A large number of further clinical studies has shown that sunitinib has multiple effects on tumour cells and can thus ...

Sunitinib in Biological Technology

Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting

...ion, Tuesday, June 3, 2008, 11:30 - 11:45 a.m., S406 - Vista Room -- Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium -- Lauren Wiebe...